BlockSec Phalcon: SharwaFinance attacked, attacker profits approximately $146,000
Foresight News reported, according to monitoring by BlockSec Phalcon, that the decentralized finance protocol SharwaFinance claimed to have been attacked and suspended its services. However, several hours later, some suspicious transactions occurred again, possibly exploiting the same underlying issue. The attacker first created a margin account, then conducted leveraged lending using the provided collateral, and finally executed a sandwich attack on the swap operation involving the borrowed assets. The root cause appears to be that the swap() function of the MarginTrading contract lacks bankruptcy checks. This function only verifies solvency based on the account status before executing the asset swap, leaving room for manipulation during the process.
The two attackers made a total profit of approximately $146,000, with attacker 1 (0xd356...c08) earning about $61,000 through multiple attacks, and attacker 2 (0xaa24...795) earning about $85,000 through a single attack.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A key leap toward the internationalization of the Korean won: The Bank of Korea launches a trial run of its 24/7 international settlement system, with full deployment set for January next year.
The Bank of Korea officially launched the trial operation of the "BOK Won International Payment Network" on Monday local time.
Offshore oil and gas module equipment company VME (VME.US) aiming for Nasdaq listing, plans to raise up to 30 million USD
Offshore oil and gas process module and separation equipment company VME Companies has applied for an IPO on Nasdaq, aiming to raise up to $30 million, with Kingswood as the sole bookrunner.
Hypertension drug developer Retension (RTSN.US) applies for US listing, plans to raise $58 million.
U.S. hypertension drug developer Retension Pharmaceuticals filed documents with the SEC last Friday, planning to raise up to $58 million through an initial public offering (IPO).
Pfizer (PFE.US) overseas price increase gains to be shared with the U.S. government: "Most Favored Nation" contract revealed, over twenty transactions still confidential
According to reports, under a new contract with the U.S. Department of Health and Human Services, Pfizer will share higher overseas drug revenues with the United States.
